Abivax Shares Surge 27% Following Promising Ulcerative Colitis Drug Trial Results

Abivax SA stock took off Tuesday, climbing about 27% in European markets after unveiling encouraging clinical trial data for its ulcerative colitis treatment, obefazimod. The French biotech reported that the drug helped patients who had previously failed initial treatment enter remission.

The company revealed that 37.2% of patients who didn't respond to the initial induction phase with obefazimod achieved clinical remission after continued treatment at a 50 mg dose by week 44. Endoscopic remission was seen in 34.5% of those patients, marking significant progress in a group typically hard to treat.

Additionally, for patients who relapsed in the maintenance period, upping the dose to 50 mg helped nearly half (45.5%) regain clinical remission. Obefazimod operates by increasing levels of microRNA miR-124, which plays a role in dialing down the body's inflammatory responses when administered orally.

These results add to the positive outcomes previously shared on June 1, where clinical remission rates at week 44 reached roughly 51% for both 25 mg and 50 mg doses, compared to just 10.4% for the placebo group.

Abivax's upcoming plan involves submitting a new drug application to the U.S. Food and Drug Administration during the fourth quarter, aiming to gain regulatory clearance for obefazimod. Given the drug's demonstrated efficacy in patients who are tougher to manage, this could be a meaningful development in ulcerative colitis treatment options.

ABVX has caught the attention of market watchers, partly due to the strength of the latest clinical data. The boost in the share price underscores investor optimism about the drug's commercial potential, especially given the chronic and often resistant nature of ulcerative colitis.

While other therapies exist for ulcerative colitis, bringing a new mechanism to the table like miR-124 modulation could carve out a unique niche if regulatory hurdles are cleared. Time will tell how the FDA responds and how the drug performs in larger patient populations.

The next few months will be critical for Abivax as it prepares its filing and keeps the spotlight on its novel approach to managing inflammation-related bowel disease.